Astria Therapeutics, Inc.
ATXS
$4.04
$0.061.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.78M | 32.54M | 30.94M | 28.85M | 25.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 111.56M | 100.97M | 92.19M | 78.49M | 67.83M |
| Operating Income | -111.56M | -100.97M | -92.19M | -78.49M | -67.83M |
| Income Before Tax | -94.26M | -100.04M | -93.24M | -81.63M | -72.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.26 | -100.04 | -93.24 | -81.63 | -72.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.26M | -100.04M | -93.24M | -81.63M | -72.89M |
| EBIT | -111.56M | -100.97M | -92.19M | -78.49M | -67.83M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.68 | -2.09 | -2.30 | -2.32 | -2.34 |
| Normalized Basic EPS | -1.05 | -1.05 | -1.18 | -1.19 | -1.20 |
| EPS Diluted | -1.68 | -2.09 | -2.30 | -2.32 | -2.34 |
| Normalized Diluted EPS | -1.05 | -1.05 | -1.18 | -1.19 | -1.20 |
| Average Basic Shares Outstanding | 224.62M | 203.09M | 173.31M | 144.84M | 120.49M |
| Average Diluted Shares Outstanding | 224.62M | 203.09M | 173.31M | 144.84M | 120.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |